27 JANUARY 2016 BIOSIMILARS DEVELOPMENT - FROM PRE-CLINIC TO MARKET Several biological products, altogether worth over US$60 billion annual sales, are encountering patent expiry byThis opens up the opportunity for - Herg - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2016-02-01 06:18:00 Pharmacology Biotechnology Biology Pharmaceutical sciences Pharmaceutical industry Biosimilar Drugs Drug discovery Biopharmaceutical Clinical trial		27 JANUARY 2016 BIOSIMILARS DEVELOPMENT - FROM PRE-CLINIC TO MARKET Several biological products, altogether worth over US$60 billion annual sales, are encountering patent expiry byThis opens up the opportunity for Add to Reading List Source URL: www.ideas-itn.eu Download Document from Source Website File Size: 456,10 KB Share Document on Facebook

	Biotechnology, BS "DBEFNJD.BQ 5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT DocID: 1xTqy - View Document
	PDF Document DocID: 1wroO - View Document
	Building A Better Mousetrap: Patenting Biotechnology In The European Community DocID: 1vr7C - View Document
	BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod DocID: 1vq6b - View Document
	Biotechnology Consultation Agency Response Letter BNF DocID: 1vpUZ - View Document